David Epstein

Diagnostic Hybrids, Inc. develops, manufactures and markets cellular and molecular diagnostic kits. Its products include rapid diagnostics, thyroid testing solutions, respiratory family testing, herpes family testing, chlamydia testing, enterovirus testing, cell lines and media and supplements. The company was founded by Wilfred R. Konneker, Joseph Jollick and Thomas E. Wagner in 1983 and is headquartered in Athens, OH.

Remedy Pharmaceuticals, Inc. develops and commercializes pharmaceutical ingridients. It focuses on small molecule drugs for acute central nervous system disorders. The company was founded by David M. Geliebter and Sven M. Jacobson in 2004 and is headquartered in New York, NY.

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.

Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ.

Woolsey Pharmaceuticals, Inc. operates as a single-drug entity. It is focused on the treatment of rare, neurodegenerative diseases with its compound BRAVYL (Fasudil). The company was founded in 2019 and is headquartered in New York, NY.

Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million.

Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The private company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.

Dynamics Special Purpose Corp. is a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination. The company was founded on March 1, 2021 and is headquartered in Redwood City, CA.

Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA.

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

OPY Acquisition Corp. I is blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded July 20, 2020 and is headquartered in New York, NY.

Pelican Harbor Seabird Station, Inc. is an animal care organization that focuses on the rehabilitation of vultures, which are the only known obligate scavengers in the world. Pelican Harbor Seabird Station is based in Miami. The organization offers behind-the-scenes tours, honorary adoptions, internships, and school & camp presentations. The American company also provides resources & referrals, seabird cruises, and self-guided audio tours. In addition, they have a photobiomodulation (PBMT) program that uses light therapy to relieve pain and inflammation.

Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.